BioNTech to Slash 1,860 Jobs as COVID Vaccine Demand Plummets

BioNTech SE, the German biotechnology company that partnered with Pfizer to develop one of the first COVID-19 vaccines, has announced plans to halt operations at several manufacturing sites, affecting as many as 1,860 jobs. The move comes as demand for its COVID-19 vaccine continues to dwindle.

The facilities impacted are located in German towns including Idar-Oberstein, Marburg, and Tübingen, as well as in Singapore. BioNTech is exploring options such as a partial or total sale of these sites to avoid outright closures, the company said in a statement on Tuesday.

This restructuring reflects the broader shift in the pharmaceutical industry as the world moves from the pandemic emergency phase to an endemic phase, where demand for COVID-19 vaccines has significantly decreased. BioNTech's decision underscores the challenges faced by companies that bet heavily on COVID-19 products, now needing to adapt to a post-pandemic market.

For workers in the affected regions, this news brings uncertainty. However, BioNTech's efforts to find buyers for the facilities could mitigate job losses if successful. The company remains a key player in mRNA technology and is investing in new therapies, including cancer vaccines, which may create future opportunities.